U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07876596) titled 'A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080' on Oct. 09.
Brief Summary: A single-center, single-arm, open-label, fixed-sequence study is planned to enroll 18 healthy participants (6-9 females). The study consists of a screening period, an observation period, and a safety follow-up period.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: HRS-8080
HRS-8080, oral.
DRUG: Rifampicin
Rifampicin, oral.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shandong Suncadia Medicine Co., Ltd.
Disclaimer: Curated by HT Syndication....